MNT: Weight Management (2015)
Citation:
Study Design:
Class:
- Click here for explanation of classification scheme.
Quality Rating:
Research Purpose:
To investigate the long-term effect of a low-fat diet with unrestricted low glycemic index (GI) carbohydrates in obese, non-diabetic patients.
Inclusion Criteria:
- Aged 18 years to 65 years
- Body mass index (BMI) 26kg/m2 to 49 kg/m2
- Willing to lose weight
- Passed medical examination
- Informed consent provided.
Exclusion Criteria:
- Use of any prescription medications
- Pregnant or breastfeeding
- Following any weight loss diet during the past three months.
Description of Study Protocol:
Recruitment
Recruited from two obesity outpatient clinics.
Design
Obese patients were recruited from two obesity clinics. Subjects were given advice on the low gylcemic index diet by a dietitian and then attended biweekly one-hour group meetings that induced dietary and supportive counseling. Body weight and body composition were measured at baseline and after 24 weeks.
Intervention
Low-fat, low glycemic index diet through education and recommendations provided by dietitian.
Statistical Analysis
- Wilcoxon signed rank test
- P<0.05 are significant.
Data Collection Summary:
Timing of Measurements
- Weight and body composition (fat mass and lean body mass) were measured at baseline and after 24 weeks
- Food diaries were completed by subjects during the last seven days of the dietary period.
Dependent Variables
- Weight
- BMI
- Fat mass
- Lean body mass.
Independent Variables
Education on low-fat, low-GI diet was provided by a dietitian.Control Variables
Compliance with low-fat, low-GI diet.
Description of Actual Data Sample:
- Initial N: N=120 subjects (66 females and 54 males)
- Attrition (final N): N=109 subjects (61 females and 48 males)
- Age: Mean age 44 years
- Anthropometrics: Differences in baseline anthropometrics not evaluated
- Location: Austria.
Summary of Results:
Key Findings
- After 24 weeks, average weight loss was 8.9kg (98.6kg vs. 89.7kg; P≤0.0001)
- Significant loss in fat mass (42.5kg vs. 36.4kg; P≤0.0001) and a decrease in lean body mass of 5.0% (56.1kg vs. 53.3kg; P≤0.0001) after 24 weeks
- Significant decrease in BMI (P≤0.0001) after 24 weeks.
Variables | Males | Females | ||||
Week Zero | Week 24 | P-value | Week Zero | Week 24 | P-value | |
Weight (kg) | 108.9±24 | 98.8±23.7 | ≤0.0001 | 90.4±13 | 82.5±11.4 | ≤0.0001 |
BMI (kg/m2) | 34.2±4.7 | 31±4.8 | ≤0.0001 | 32.7±4.0 | 29.8±3.5 | ≤0.0001 |
Fat mass (kg) | 47.9±11.2 | 41.1±11 | ≤0.0001 | 38.2±8.5 | 32.7±7.1 | ≤0.0001 |
Lean body mass (kg) | 61.1±15.1 | 57.7±15.3 | ≤0.0001 | 52.2±7.5 | 49.8±7.0 | ≤0.0001 |
Data expressed as mean ±SD.
Other Findings
Adherence to diet:- Category one (adhered exactly to advice given): 60% of subjects
- Category two (did not completely adhere to advice given but dietary intake was acceptable): 31% of subjects
- Category three (did not adhere to advice given and dietary intake was unacceptable): 9% of subjects.
Author Conclusion:
The six-month uncontrolled study using a low-fat, low-GI diet led to a significant reduction in body mass and fat mass with a considerable smaller reduction in lean body mass. Good adherence to the diet and a low dropout rate were observed.
Funding Source:
Other: | Not described |
Reviewer Comments:
- Study did not have control group
- Attendance at group meetings was not described.
Quality Criteria Checklist: Primary Research
|
|||
Relevance Questions | |||
1. | Would implementing the studied intervention or procedure (if found successful) result in improved outcomes for the patients/clients/population group? (Not Applicable for some epidemiological studies) | Yes | |
2. | Did the authors study an outcome (dependent variable) or topic that the patients/clients/population group would care about? | Yes | |
3. | Is the focus of the intervention or procedure (independent variable) or topic of study a common issue of concern to dieteticspractice? | Yes | |
4. | Is the intervention or procedure feasible? (NA for some epidemiological studies) | Yes | |
Validity Questions | |||
1. | Was the research question clearly stated? | Yes | |
1.1. | Was (were) the specific intervention(s) or procedure(s) [independent variable(s)] identified? | Yes | |
1.2. | Was (were) the outcome(s) [dependent variable(s)] clearly indicated? | Yes | |
1.3. | Were the target population and setting specified? | Yes | |
2. | Was the selection of study subjects/patients free from bias? | Yes | |
2.1. | Were inclusion/exclusion criteria specified (e.g., risk, point in disease progression, diagnostic or prognosis criteria), and with sufficient detail and without omitting criteria critical to the study? | Yes | |
2.2. | Were criteria applied equally to all study groups? | Yes | |
2.3. | Were health, demographics, and other characteristics of subjects described? | Yes | |
2.4. | Were the subjects/patients a representative sample of the relevant population? | Yes | |
3. | Were study groups comparable? | N/A | |
3.1. | Was the method of assigning subjects/patients to groups described and unbiased? (Method of randomization identified if RCT) | N/A | |
3.2. | Were distribution of disease status, prognostic factors, and other factors (e.g., demographics) similar across study groups at baseline? | N/A | |
3.3. | Were concurrent controls or comparisons used? (Concurrent preferred over historical control or comparison groups.) | N/A | |
3.4. | If cohort study or cross-sectional study, were groups comparable on important confounding factors and/or were preexisting differences accounted for by using appropriate adjustments in statistical analysis? | N/A | |
3.5. | If case control study, were potential confounding factors comparable for cases and controls? (If case series or trial with subjects serving as own control, this criterion is not applicable.) | N/A | |
3.6. | If diagnostic test, was there an independent blind comparison with an appropriate reference standard (e.g., "gold standard")? | N/A | |
4. | Was method of handling withdrawals described? | Yes | |
4.1. | Were follow-up methods described and the same for all groups? | Yes | |
4.2. | Was the number, characteristics of withdrawals (i.e., dropouts, lost to follow up, attrition rate) and/or response rate (cross-sectional studies) described for each group? (Follow up goal for a strong study is 80%.) | Yes | |
4.3. | Were all enrolled subjects/patients (in the original sample) accounted for? | Yes | |
4.4. | Were reasons for withdrawals similar across groups? | Yes | |
4.5. | If diagnostic test, was decision to perform reference test not dependent on results of test under study? | N/A | |
5. | Was blinding used to prevent introduction of bias? | Yes | |
5.1. | In intervention study, were subjects, clinicians/practitioners, and investigators blinded to treatment group, as appropriate? | No | |
5.2. | Were data collectors blinded for outcomes assessment? (If outcome is measured using an objective test, such as a lab value, this criterion is assumed to be met.) | Yes | |
5.3. | In cohort study or cross-sectional study, were measurements of outcomes and risk factors blinded? | N/A | |
5.4. | In case control study, was case definition explicit and case ascertainment not influenced by exposure status? | N/A | |
5.5. | In diagnostic study, were test results blinded to patient history and other test results? | N/A | |
6. | Were intervention/therapeutic regimens/exposure factor or procedure and any comparison(s) described in detail? Were interveningfactors described? | Yes | |
6.1. | In RCT or other intervention trial, were protocols described for all regimens studied? | N/A | |
6.2. | In observational study, were interventions, study settings, and clinicians/provider described? | Yes | |
6.3. | Was the intensity and duration of the intervention or exposure factor sufficient to produce a meaningful effect? | Yes | |
6.4. | Was the amount of exposure and, if relevant, subject/patient compliance measured? | Yes | |
6.5. | Were co-interventions (e.g., ancillary treatments, other therapies) described? | No | |
6.6. | Were extra or unplanned treatments described? | No | |
6.7. | Was the information for 6.4, 6.5, and 6.6 assessed the same way for all groups? | Yes | |
6.8. | In diagnostic study, were details of test administration and replication sufficient? | N/A | |
7. | Were outcomes clearly defined and the measurements valid and reliable? | Yes | |
7.1. | Were primary and secondary endpoints described and relevant to the question? | Yes | |
7.2. | Were nutrition measures appropriate to question and outcomes of concern? | Yes | |
7.3. | Was the period of follow-up long enough for important outcome(s) to occur? | Yes | |
7.4. | Were the observations and measurements based on standard, valid, and reliable data collection instruments/tests/procedures? | Yes | |
7.5. | Was the measurement of effect at an appropriate level of precision? | Yes | |
7.6. | Were other factors accounted for (measured) that could affect outcomes? | Yes | |
7.7. | Were the measurements conducted consistently across groups? | Yes | |
8. | Was the statistical analysis appropriate for the study design and type of outcome indicators? | Yes | |
8.1. | Were statistical analyses adequately described and the results reported appropriately? | Yes | |
8.2. | Were correct statistical tests used and assumptions of test not violated? | Yes | |
8.3. | Were statistics reported with levels of significance and/or confidence intervals? | Yes | |
8.4. | Was "intent to treat" analysis of outcomes done (and as appropriate, was there an analysis of outcomes for those maximally exposed or a dose-response analysis)? | No | |
8.5. | Were adequate adjustments made for effects of confounding factors that might have affected the outcomes (e.g., multivariate analyses)? | No | |
8.6. | Was clinical significance as well as statistical significance reported? | Yes | |
8.7. | If negative findings, was a power calculation reported to address type 2 error? | N/A | |
9. | Are conclusions supported by results with biases and limitations taken into consideration? | Yes | |
9.1. | Is there a discussion of findings? | Yes | |
9.2. | Are biases and study limitations identified and discussed? | No | |
10. | Is bias due to study's funding or sponsorship unlikely? | Yes | |
10.1. | Were sources of funding and investigators' affiliations described? | No | |
10.2. | Was the study free from apparent conflict of interest? | Yes | |